Thomas Berg
About
Thomas Berg is a scholar working on Hepatology, Epidemiology and Infectious Diseases.
According to data from OpenAlex, Thomas Berg has authored 726 papers receiving a total of 28.1k indexed citations (citations by other indexed papers that have themselves been cited), including 515 papers in Hepatology, 474 papers in Epidemiology and 88 papers in Infectious Diseases. Recurrent topics in Thomas Berg's work include Hepatitis C virus research (401 papers), Liver Disease Diagnosis and Treatment (320 papers) and Hepatitis B Virus Studies (256 papers). Thomas Berg is often cited by papers focused on Hepatitis C virus research (401 papers), Liver Disease Diagnosis and Treatment (320 papers) and Hepatitis B Virus Studies (256 papers). Thomas Berg collaborates with scholars based in Germany, United States and France. Thomas Berg's co-authors include Marı́a Buti, Pietro Lampertico, Harry L.A. Janssen, Kosh Agarwal, Fabien Zoulim, Frank Tacke, George Papatheodoridis, Stefan Zeuzem, Florian van Bömmel and Ulrich Spengler and has published in prestigious journals such as Science, New England Journal of Medicine and Journal of Biological Chemistry.
In The Last Decade
Thomas Berg
682 papers receiving 27.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Thomas Berg Germany | 73 | 20.4k | 20.3k | 3.2k | 2.1k | 2.1k | 726 | 28.1k | ||
| Masashi Mizokami Japan | 73 | 16.1k 0.8× | 16.3k 0.8× | 2.2k 0.7× | 2.6k 1.3× | 1.4k 0.7× | 489 | 21.8k | ||
| Raymond T. Chung United States | 79 | 12.9k 0.6× | 13.5k 0.7× | 2.6k 0.8× | 3.7k 1.8× | 3.1k 1.5× | 431 | 23.1k | ||
| Heiner Wedemeyer Germany | 82 | 19.8k 1.0× | 23.1k 1.1× | 4.5k 1.4× | 1.8k 0.8× | 3.9k 1.9× | 840 | 29.2k | ||
| Jean–Michel Pawlotsky France | 82 | 17.6k 0.9× | 19.7k 1.0× | 3.5k 1.1× | 2.4k 1.2× | 1.5k 0.7× | 467 | 24.6k | ||
| Nezam H. Afdhal United States | 76 | 13.2k 0.6× | 13.2k 0.7× | 1.4k 0.4× | 2.2k 1.1× | 1.1k 0.5× | 343 | 19.6k | ||
| David L. Thomas United States | 72 | 21.0k 1.0× | 21.7k 1.1× | 4.2k 1.3× | 1.2k 0.6× | 2.6k 1.2× | 292 | 27.3k | ||
| Harry L.A. Janssen Netherlands | 82 | 21.4k 1.0× | 20.9k 1.0× | 1.9k 0.6× | 2.9k 1.4× | 3.3k 1.6× | 430 | 29.0k | ||
| Zachary Goodman United States | 88 | 33.3k 1.6× | 31.0k 1.5× | 3.4k 1.0× | 3.0k 1.4× | 1.2k 0.6× | 299 | 42.1k | ||
| Patrick Marcellin France | 99 | 34.3k 1.7× | 34.2k 1.7× | 4.1k 1.3× | 1.4k 0.7× | 1.3k 0.6× | 635 | 38.8k | ||
| Stanislas Pol France | 71 | 14.2k 0.7× | 15.1k 0.7× | 3.1k 1.0× | 925 0.4× | 1.1k 0.5× | 484 | 18.9k |
Countries citing papers authored by Thomas Berg
Since
Specialization
Citations
This map shows the geographic impact of Thomas Berg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Berg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Berg more than expected).
Fields of papers citing papers by Thomas Berg
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Thomas Berg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Berg. The network helps show where Thomas Berg may publish in the future.
Co-authorship network of co-authors of Thomas Berg
This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Berg. A scholar is included among the top collaborators of Thomas Berg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Berg. Thomas Berg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Matz‐Soja, Madlen, Thomas Berg, & Thomas Kietzmann. (2025). Sex-related variations in liver homeostasis and disease: From zonation dynamics to clinical implications. Journal of Hepatology. 84(1). 181–193.
2.
Jäger, Kathrin, et al.. (2024). Use of Bacterial DNA Concentration in Ascites as a Marker for Spontaneous Bacterial Peritonitis. Journal of Clinical and Experimental Hepatology. 14(5). 101434–101434.
3.
Martino, Vincent Di, Delphine Weil, Cornelius Engelmann, et al.. (2023). Granulocyte colony stimulating factor in decompensated cirrhosis, acute alcoholic hepatitis, and acute-on-chronic liver failure: A comprehensive meta-analysis of randomized controlled trials. Clinics and Research in Hepatology and Gastroenterology. 47(9). 102207–102207.
4.
Peters, Marion G., Man‐Fung Yuen, Norah A. Terrault, et al.. (2023). Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes. Clinical Infectious Diseases. 78(4). 983–990.
5.
Gibb, Sebastian, Thomas Berg, Adam Herber, Berend Isermann, & Thorsten Kaiser. (2023). A new machine-learning-based prediction of survival in patients with end-stage liver disease. Journal of Laboratory Medicine. 47(1). 13–21.
6.
Fischer, Janett, Tobias Müller, R Heyne, et al.. (2023). Sex‐differences in the association of interleukin‐10 and interleukin‐12 variants with the progression of hepatitis B virus infection in Caucasians. Hepatology Research. 53(12). 1156–1168.
7.
Engelmann, Cornelius, Abeba Habtesion, Mohsin Hassan, et al.. (2022). Combination of G-CSF and a TLR4 inhibitor reduce inflammation and promote regeneration in a mouse model of ACLF. Journal of Hepatology. 77(5). 1325–1338.
8.
Fischer, Janett, Sebastian Ebel, Thomas Lincke, et al.. (2022). The Liver Maximum Capacity Test (LiMAx) Is Associated with Short-Term Survival in Patients with Early Stage HCC Undergoing Transarterial Treatment. Cancers. 14(21). 5323–5323.
9.
Mücke, Victoria T., Janett Fischer, Marcus M. Mücke, et al.. (2022). Association of Alpha-1 Antitrypsin Pi*Z Allele Frequency and Progressive Liver Fibrosis in Two Chronic Hepatitis C Cohorts. Journal of Clinical Medicine. 12(1). 253–253.
10.
Ebel, Sebastian, Martin Reinhardt, Manuel F. Struck, et al.. (2022). Analysis of patient’s X-ray exposure in hepatic chemosaturation procedures: a single center experience. BMC Medical Imaging. 22(1). 165–165.
11.
Russo, Francesco Paolo, Manhal Izzy, Ashwin Rammohan, et al.. (2021). Global impact of the first wave of COVID-19 on liver transplant centers: A multi-society survey (EASL-ESOT/ELITA-ILTS). Journal of Hepatology. 76(2). 364–370.
12.
Stindt, Jan, et al.. (2021). Autoantibody formation against a canalicular epitope found in a patient with acute intrahepatic cholestasis with PFIC-like presentation. JHEP Reports. 4(2). 100418–100418.
13.
Petersen, Jörg, Wolf Peter Hofmann, Holger Hinrichsen, et al.. (2021). Real-World Clinical Management of Patients with Primary Biliary Cholangitis—A Retrospective Multicenter Study from Germany. Journal of Clinical Medicine. 10(5). 1061–1061.
14.
Efe, Cumali, Henriette Ytting, Rahima A. Bhanji, et al.. (2018). Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis. Digestive Diseases and Sciences. 63(5). 1348–1354.
15.
Solbach, Philipp, Sandra Westhaus, Eva Herrmann, et al.. (2015). Oxidized Low-Density Lipoprotein Is a Novel Predictor of Interferon Responsiveness in Chronic Hepatitis C Infection. Cellular and Molecular Gastroenterology and Hepatology. 1(3). 285–294.e1.
16.
Berg, Thomas, Pietro Andreoné, Stanislas Pol, et al.. (2014). Low‐density lipoprotein and other predictors of response with telaprevir‐based therapy in treatment‐experienced HCV genotype 1 patients: REALIZE study. Liver International. 35(2). 448–454.
17.
Dieterich, Douglas T., Tarik Asselah, Dominique Guyader, et al.. (2014). SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients. Antimicrobial Agents and Chemotherapy. 58(6). 3429–3436.
18.
Berg, Thomas, et al.. (2008). Effects of Curcumin on Tumor Growth and Muscle Mass in a Mouse Model of Cancer Cachexia. Oncology nursing forum. 35(3). 455–459.
19.
Berg, Thomas, E. Schreier, Uta Naumann, et al.. (2008). Hepatitis-G-Virus-Infektion: epidemiologische Aspekte und klinische Relevanz. DMW - Deutsche Medizinische Wochenschrift. 122(9). 268–274.
20.
Feldmann, Georg, Hans Dieter Nischalke, Jacob Nattermann, et al.. (2006). Induction of Interleukin-6 by Hepatitis C Virus Core Protein in Hepatitis C–Associated Mixed Cryoglobulinemia and B-Cell Non–Hodgkin's Lymphoma. Clinical Cancer Research. 12(15). 4491–4498.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Masashi Mizokami Breakdown of academic impact, for papers by Raymond T. Chung Breakdown of academic impact, for papers by Heiner Wedemeyer Breakdown of academic impact, for papers by Jean–Michel Pawlotsky Breakdown of academic impact, for papers by Nezam H. Afdhal Breakdown of academic impact, for papers by David L. Thomas Breakdown of academic impact, for papers by Harry L.A. Janssen Breakdown of academic impact, for papers by Zachary Goodman Breakdown of academic impact, for papers by Patrick Marcellin Breakdown of academic impact, for papers by Stanislas Pol